Neurology. 1978 Nov;28(11):1094-8.

Baclofen for spasticity in multiple sclerosis. Double-blind crossover and three-year study.

Feldman RG, Kelly-Hayes M, Conomy JP, Foley JM.

Abstract

Baclofen is a safe and effective means for treating spasticity associated with multiple sclerosis. We found no toxic effects on hepatologic, hematopoietic, or renal function, acutely or for over 3 years of follow-up. A statistically significant reduction was noted in frequency of spasms, and clonus, and there was improved range of joint movement, which enabled patients to maintain functional status for prolonged periods. For the more disabled patients, treatment with baclofen gave symptomatic relief of painful spasms and made immobility more tolerable. Optimum effect was achieved when baclofen was administered in the early stages of disease, before major disabilities became permanent.

PMID:: 362234; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Ovid Technologies, Inc.

Medical

Multiple Sclerosis - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

The use of baclofen in treatment of spasticity in multiple sclerosis. [Can J Neurol Sci. 1979]
The use of baclofen in treatment of spasticity in multiple sclerosis.
Sawa GM, Paty DW. Can J Neurol Sci. 1979 Aug; 6(3):351-4.
Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis. [Arch Neurol. 1977]
Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis.
Sachais BA, Logue JN, Carey MS. Arch Neurol. 1977 Jul; 34(7):422-8.
A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. [Curr Med Res Opin. 1981]
A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
Smolenski C, Muff S, Smolenski-Kautz S. Curr Med Res Opin. 1981; 7(6):374-83.
Review A benefit-risk assessment of baclofen in severe spinal spasticity. [Drug Saf. 2004]
Review A benefit-risk assessment of baclofen in severe spinal spasticity.
Dario A, Tomei G. Drug Saf. 2004; 27(11):799-818.
Review Treatments for spasticity and pain in multiple sclerosis: a systematic review. [Health Technol Assess. 2003]
Review Treatments for spasticity and pain in multiple sclerosis: a systematic review.
Beard S, Hunn A, Wight J. Health Technol Assess. 2003; 7(40):iii, ix-x, 1-111.

See reviews... See all...

Cited by 3 PubMed Central articles

Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice. [Ther Adv Neurol Disord. 2011]
Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice.
de Sa JC, Airas L, Bartholome E, Grigoriadis N, Mattle H, Oreja-Guevara C, O'Riordan J, Sellebjerg F, Stankoff B, Vass K, et al. Ther Adv Neurol Disord. 2011 May; 4(3):139-68.
Neurology-epitomes of progress: lioresal. [West J Med. 1980]
Neurology-epitomes of progress: lioresal.
Ellison GW. West J Med. 1980 Feb; 132(2):142.
Status epilepticus after baclofen withdrawal. [J Natl Med Assoc. 1984]
Status epilepticus after baclofen withdrawal.
Hyser CL, Drake ME Jr. J Natl Med Assoc. 1984 May; 76(5):533, 537-8.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.
Cited in Books
NCBI Bookshelf books that cite the current articles.

Recent activity

Clear Turn Off Turn On

Baclofen for spasticity in multiple sclerosis. Double-blind crossover and three-...
Baclofen for spasticity in multiple sclerosis. Double-blind crossover and three-year study.
Neurology. 1978 Nov ;28(11):1094-8.

PubMed
[An automatic implantable cardioverter-defibrillator. The initial clinical exper...
[An automatic implantable cardioverter-defibrillator. The initial clinical experience].
Dtsch Med Wochenschr. 1987 Aug 28 ;112(35):1323-30.

PubMed
A biomechanical evaluation of sorbothane.
A biomechanical evaluation of sorbothane.
Clin Orthop Relat Res. 1987 Sep ;(222):281-8.

PubMed
Correlation between the serine sensitivity and the derepressibility of the ilv g...
Correlation between the serine sensitivity and the derepressibility of the ilv genes in Escherichia coli relA- mutants.
Mol Gen Genet. 1978 Sep 20 ;165(1):21-30.

PubMed
Regulation of low-density lipoprotein receptors: implications for pathogenesis a...
Regulation of low-density lipoprotein receptors: implications for pathogenesis and therapy of hypercholesterolemia and atherosclerosis.
Circulation. 1987 Sep ;76(3):504-7.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Baclofen for spasticity in multiple sclerosis. Double-blind crossover and three-year study.

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Cited by 3 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information